Gitnux/Report 2026

Ketamine Clinic Industry Statistics

The global ketamine clinic market is estimated at $1.55 billion in 2026, explore company operating models, treatment formats, and regulatory trends driving growth.
12Statistics
24Sources
2Sections
1Visuals
13mRead
Ketamine Clinic Industry Statistics
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The ketamine clinic industry at a glance

The global ketamine clinic market was estimated at $1.42 billion in 2025 and is projected to reach $1.55 billion in 2026, as supervised in-clinic treatment expands alongside regulated esketamine services.

$1.42B[3]
Global market size, 2025
10.32%[3]
Forecast CAGR, 2026–2031
53.86%[3]
North America share, 2025
46.59%[3]
Intravenous delivery share, 2025
Market size
The global ketamine clinic market was valued at $1.42 billion in 2025 and is estimated at $1.55 billion in 2026. These figures are proprietary market estimates rather than official national accounts.[3]
Forecast & CAGR
The market is forecast to reach $2.53 billion by 2031, implying a 10.32% compound annual growth rate from 2026 to 2031. Asia-Pacific is projected to be the fastest-growing regional component, with an 11.64% CAGR through 2031.[3]
Market share & regions
North America accounted for 53.86% of the global ketamine clinic market in 2025, making it the largest regional market. Europe was identified as the second-largest regional segment, while Asia-Pacific is expected to grow fastest through 2031.[3]
Segmentation
Intravenous delivery held 46.59% of the market in 2025, while medication-only services accounted for 69.13%. Independently owned private clinics represented 36.32%, and adults represented 45.76% of the patient age-group segment.[3]
Key players & concentration
The market is fragmented across independent clinics, telehealth providers, hospital-affiliated services and interventional-psychiatry groups; the largest independently owned private-clinic category held 36.32% of the market in 2025. No reliable source reviewed disclosed a consolidated market share for the leading individual companies.[3]
Pricing
Published self-pay prices vary by clinic and treatment format. One U.S. clinic lists an IV ketamine treatment at $500 per session, or $750 when psychotherapy is added; its discounted prices are $250 and $350, respectively.[6]
Trends, drivers & challenges
Growth is being driven by demand for treatment-resistant-depression services, expansion of supervised esketamine access and growth in telehealth. The market also faces uneven clinical practice, self-pay affordability barriers and tighter scrutiny of compounded ketamine and remote prescribing.[7][8][9]
Consumer behavior & competition
Direct-to-consumer and self-referred patients represented 43.62% of the market in 2025, indicating a substantial consumer-led acquisition channel. In Charlotte, one provider reported more than 1,000 patients treated and more than 5,000 infusions since opening in 2023, illustrating local competition among clinic networks.[3][10]
M&A
M&A activity is emerging around integrated interventional-psychiatry platforms. In September 2025, HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, completed its acquisition of Dura Medical, a Florida practice offering ketamine infusion therapy, Spravato, TMS and related psychiatric services.[11]
Regulation
Ketamine is listed by the U.S. Drug Enforcement Administration as a Schedule III controlled substance. FDA-approved Spravato is indicated for adults with treatment-resistant depression and is subject to a Risk Evaluation and Mitigation Strategy, while much IV racemic-ketamine clinic use remains off-label.[12][7]
Latest news
In 2026, FDA enforcement activity continued to focus on ketamine marketing and compounded products: a June 2026 warning letter to Keta Med Lab cited claims for ketamine nasal spray and highlighted risks associated with sedation, dissociation, respiratory depression and misuse. The FDA also approved a modified Spravato REMS in 2025.[8][7]

02 Ranking

Top 10 Companies in the Ketamine Clinic Industry

The leading companies in the ketamine clinic industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Stella stands out for multimodal ketamine and interventional mental health clinics because it operates more than 20 locations across over 10 U.S. states, while Joyous focuses on at-home low-dose ketamine since it prescribes low-dose ketamine with recurring clinical check-ins.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in multimodal interventional psychiatry

    Stella

    US

    Ranked #1 · 9.5 · Multimodal interventional psychiatry

    Why we picked it: It runs multimodal ketamine and interventional mental health clinics, with ketamine infusion therapy across more than 20 locations.

  2. Leader in at-home low-dose ketamine

    Joyous

    US

    Ranked #2 · 9.5 · At-home low-dose ketamine

    Why we picked it: It focuses on low-dose at-home ketamine, using recurring clinical check-ins to monitor patients over time.

  3. Leader in at-home oral ketamine

    Better U

    US

    Ranked #3 · 9.3 · At-home oral ketamine

    Why we picked it: It pairs at-home oral ketamine with structured integration support, and reports an operating margin of 1.5%.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the ketamine clinic industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Stella

Multimodal interventional psychiatry · US

9.5
2

Joyous

At-home low-dose ketamine · US

9.5
3

Better U

At-home oral ketamine · US

9.3
4

Ketamine Clinics Los Angeles

IV ketamine clinics · US

8.7
5

Ember Health

IV ketamine clinics · US

8.5
6

Mindbloom

At-home clinician-supervised ketamine therapy · US

8.4
7

Journey Clinical

KAP and Spravato care network across the U.S. · US

7.9
8

Keta Medical Center

IV ketamine and Spravato clinics in NY and NJ · US

7.8
9

NY Ketamine Infusions

Ketamine and Spravato clinics in New York · US

7.8
10

Klarisana

Ketamine therapy clinics in Texas and Colorado · US

7.6

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 10 companies in the ketamine clinic industry. In Ketamine Clinic Industry Statistics. Gitnux. https://gitnux.org/ketamine-clinic-industry-statistics/#top-companies

report visual · Breakdown

U.S. ketamine clinics market share by therapy modality

On-site therapy holds the largest share at 81.2%.

81.2%
On-site therapy
18.8%
Online therapy
source-verifiedmordorintelligence.com

04 Statistics

Market Intelligence

Market intelligence ties 2025 size of $1.42 billion to a 2026 estimate of $1.55 billion, with North America at a 53.86% share in 2025.

Market size and service revenue in the ketamine clinic industry

  • $1.32 billion was the 2025 global ketamine clinic market size, covering clinic-based and online ketamine therapy services across treatment, referral, administration and end-user segments.[1]
  • $1.60 billion was the estimated 2026 global ketamine clinic market size, covering on-site and online ketamine therapy services across geographic and treatment segments.[2]
  • $1.42 billion was the 2025 global ketamine clinic market size, covering treatment, therapy, referral-source, administration-mode and end-user segments.[3]

Growth forecasts for the ketamine clinic industry

  • The global ketamine clinic market is projected to reach $3.42 billion by 2033, representing an 11.4% CAGR from 2026 to 2033.[2]
  • The global ketamine clinic market is projected to reach $2.07 billion by 2030, representing a 9.3% CAGR from 2025 to 2030.[1]
  • The global ketamine clinic market is projected to reach $2.53 billion by 2031, representing a 10.32% CAGR from 2026 to 2031.[3]

Regional breakdown of the ketamine clinic industry

  • North America held 53.86% of the global ketamine clinic market in 2025, making it the largest regional contributor.[3]
  • Europe accounted for $757.1 million of the 2025 global ketamine clinics market, within a global market estimated at $3.87 billion.[4]
  • North America accounted for $1.64 billion of the 2025 global ketamine clinics market, within a global market estimated at $3.87 billion.[4]

05 Statistics

Risk & Compliance

Risk and compliance centers on HIPAA breach mechanics: a 500-individual threshold triggers immediate Secretary notification, and affected individuals must be notified within 60 days.

Client data and confidentiality in the ketamine clinic industry

  • 500 individuals is the breach-size threshold triggering immediate Secretary notification for U.S. ketamine clinics covered by HIPAA; smaller breaches may be reported annually.[5]
  • 60 days is the maximum period for U.S. ketamine clinics that are HIPAA covered entities to notify affected individuals after discovering a breach of unsecured protected health information.[5]
  • 90 days is the minimum period for substitute website notice and continued toll-free telephone availability when a HIPAA-covered ketamine clinic lacks current contact information for 10 or more affected individuals.[5]

Key questions about the ketamine clinic industry

What was the global ketamine clinic market size in 2025 and 2026?
The global ketamine clinic market was estimated at $1.42 billion in 2025 and is projected to reach $1.55 billion in 2026.
How fast is the market expected to grow from 2026 to 2031?
The market is forecast to reach $2.53 billion by 2031, implying a 10.32% compound annual growth rate from 2026 to 2031.
Which companies lead the ketamine clinic industry?
Stella stands out for multimodal ketamine and interventional mental health clinics because it operates more than 20 locations across over 10 U.S. states, while Joyous focuses on at-home low-dose ketamine since it prescribes low-dose ketamine with recurring clinical check-ins.
What technology or care-delivery shifts matter for ketamine clinics?
Delivery format matters: intravenous delivery held 46.59% of the market in 2025, while medication-only services accounted for 69.13%. Telehealth is also shifting toward tighter supervision.
How is the market structured in terms of ownership and channels?
Independently owned private clinics represented 36.32% of the market in 2025, and direct-to-consumer and self-referred patients represented 43.62% of the market in 2025.
What compliance timelines apply for HIPAA breach notifications at U.S. ketamine clinics?
A 500-individual breach-size threshold triggers immediate Secretary notification, and clinics have up to 60 days to notify affected individuals after discovering an unsecured protected health information breach.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Ketamine Clinic Industry Statistics. Gitnux. https://gitnux.org/ketamine-clinic-industry-statistics
MLA
Samuel Norberg. "Ketamine Clinic Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/ketamine-clinic-industry-statistics.
Chicago
Samuel Norberg. 2026. "Ketamine Clinic Industry Statistics." Gitnux. https://gitnux.org/ketamine-clinic-industry-statistics.